Cyclophosphamide after transplant reduced GVHD in myeloma patientsNovember 20, 2017Lymphoma & Plasma Cell Disorders
FDA approves obinutuzumab for follicular lymphomaNovember 17, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Rituximab key to survival after transplant for mantle cell lymphomaNovember 16, 2017Lymphoma & Plasma Cell Disorders
Debate: Is MRD ready for prime time in multiple myeloma?November 15, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Lenalidomide shows clinical activity in relapsed/refractory MCLNovember 10, 2017Lymphoma & Plasma Cell Disorders
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphomaNovember 9, 2017Lymphoma & Plasma Cell Disorders
Event-free survival at 24 months predicts outcomes in peripheral T-cell lymphomasNovember 2, 2017Lymphoma & Plasma Cell Disorders
FDA approves acalabrutinib for second-line treatment of MCLOctober 31, 2017Lymphoma & Plasma Cell Disorders
Rituximab improves salvage in elderly B-cell lymphoma patientsOctober 23, 2017Lymphoma & Plasma Cell Disorders
Irradiation safe, effective as chemotherapy before cell transplant in mantle cell lymphomaOctober 23, 2017Lymphoma & Plasma Cell Disorders
Obinutuzumab edges out rituximab for PFS in follicular lymphomaOctober 6, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
VCR regimen showed efficacy in mantle cell and indolent lymphomasOctober 6, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Adding bortezomib to R-CHOP didn’t improve survival in diffuse large B-cell lymphomaSeptember 29, 2017Lymphoma & Plasma Cell Disorders
